“C-POST protocol update: A Phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post surgery and radiation therapy in patients with high-risk cutaneous squamous cell carcinoma” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s173. doi:10.25251/skin.7.supp.173.